80%Confidence
0Views
FDASource
2026-03-30Date
Summary
Harbin Jixianglong's Semaglutide recall due to incomplete validation processes reveals significant regulatory compliance failures in the competitive weight loss drug compounding market. This creates opportunity for competitors but raises concerns about quality control in the compounding pharmacy supply chain.
Actionable: Research alternative suppliers of compounding Semaglutide that have stronger regulatory compliance records.
AI Confidence: 80%
Data Points
firmHarbin Jixianglong Biotech Co., Ltd.
classificationClass II
statusOngoing
distributionNationwide within the United States
productSemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now